Role of medication therapy management in preexposure prophylaxis therapy for HIV prevention

J Pharm Pract. 2015 Feb;28(1):10-2. doi: 10.1177/0897190014562351. Epub 2014 Dec 10.


Patient medication adherence is a long-standing problem and is one that raises serious issues for patient health, public health, and health care quality. Medication nonadherence costs the US economy an estimated US$290 billion in avoidable medical spending every year. One of the most costly health conditions is HIV disease, which continues to be a serious health issue for parts of the world. About 34 million people are living with HIV around the world. With the emerging preventative treatment against HIV, known as preexposure prophylaxis (PrEP), come concerns surrounding the potential impact of nonadherence to this newly approved medication therapy. Nonadherence to antiretroviral treatments are commonly the root cause for patients not reaching their treatment goals, putting them at risk of progression and worsening of their disease and complications, such as increased risk of opportunistic infections. Therefore, it is essential to improve antiretroviral medication adherence. By identifying members who are nonadherent to their prescribed antiretroviral medications and working collaboratively with patients, physicians, and pharmacists, Medication Therapy Management (MTM) can potentially increase medication adherence by helping patients identify, resolve, and prevent issues that may affect their decision not to take a medication as intended.

Keywords: HIV; MTM; PrEP; antiretroviral therapy; emtricitabine/tenofovir disoproxil; medication adherence; medication therapy management; preexposure prophylaxis.

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / pharmacology
  • HIV Infections / prevention & control*
  • Humans
  • Medication Adherence*
  • Medication Therapy Management / organization & administration*
  • Pharmaceutical Services
  • Pre-Exposure Prophylaxis / methods*


  • Anti-HIV Agents